Design your studies for success.

Only Synchrony Labs combines exclusive access to internationally-acclaimed clinical investigators and state-of-the-art imaging technology to develop cardiovascular studies with unprecedented clinical - experimental research concordance
Image of a heart
CUTTING-EDGE TECHNOLOGICAL
CAPABILITIES
INTERNATIONALLY
ACCLAIMED
INVESTIGATORS
EXCLUSIVE
ANALYTICS
SOFTWARE
With more than 80% of our preclinical work focused on the areas of cardiovascular and structural heart research, we believe our industry expertise in heart research gives our clients the edge in expediting their innovation pipeline.
CARDIOVASCULAR INTERVENTIONAL
CARDIOVASCULAR SURGICAL
STRUCTURAL HEART
With more than 80% of our preclinical work focused on the areas of cardiovascular and structural heart research, we believe our industry expertise in heart research gives our clients the edge in expediting their innovation pipeline.
Cardiovascular Interventional
Cardiovascular Surgical
Cardiovascular Electrophysiological
Structural Heart
Image of the Cardiovascular Masters Consortium logo
REAL-TIME CONSULTANT INSIGHTS AND FEEDBACK
Unique access to internationally recognized KOLs in cardiology, structural heart, interventional cardiology and cardiovascular surgery.

Meet the
experts of
the CMC

3700+

published studies

200+

PATENTS
Carmello Milano, MD
Heart Transplant Surgeon

Chief, Adult Cardiac Surgery, Duke University (one of top 3 largest heart transplant programs in the world)

Editor, American Journal of Cardiology
Randolph Chitwood, MD
Past president, Society of Thoracic Surgeons, the International Society for Minimally Invasive Cardiothoracic Surgery, the International Society for Heart Valve Disease, and the North Carolina Chapter of the American Heart Association

Leading international pioneer in minimally invasive and robotic heart surgery; he and his team have personally performed the first robotic heart operations in ten countries

Research activities relate to myocardial preservation, simulation in surgery, and endoscopic/robotic cardiac surgery

Principle investigator of the FDA robotic mitral valve trials that led to approval for use in the United States
Manesh Patel, MD
Chief of Cardiology and Chief of Clinical Pharmacology

RS Stack Endowed Professor, Interventional Cardiology, Duke University

American Heart Association Chairman, Scientific Sessions, 2021
Christopher O’Connor, MD
Editor-In-Chief, Heart Failure Journal, American College of Cardiology

President and Executive Director, Inova Heart and Vascular Institute

Professor (adjunct) and previous RS Stack Endowed Professor, Duke University
William O'Neill, MD
Master Operator, SCAI, and internationally recognized leader in interventional and structural heart disease

Pioneered the use of angioplasty for treatment of heart attacks, which is now the mainstay therapy throughout the world

Performed the first aortic valve replacement through a catheter in the U.S. in 2005
Thomas Caranasos, MD
Cardiothoracic surgeon

Conducting research with bioengineers from North Carolina State University Department of Bioengineering in the field of regenerative medicine, specifically in stem cell research and its role in the cardiac and thoracic patient.
Brian O’Neill, MD
Interventional Cardiologist

Board Certified by The American Board of Internal Medicine for Cardiovascular Disease and Interventional Cardiology

Served as Assistant Professor of Medicine at Temple University Hospital in Philadelphia
Susan Joseph, MD
Chief, Advanced Heart Failure and Cardiac Transplantation at the
University of Maryland

The heart transplantation specialist who succeeded in treating the world’s first porcine to human heart transplant
Dee Dee Wang, MD, FACC, FASE, FSCCT
Thought leader in all imaging modalities for structural heart intervention

Specializing in high-risk interventional imaging in structural heart interventions including transcatheter mitral valve replacement therapies, tricuspid interventions, MitraClip, complex TAVRs/adult-congenital cases, LAA interventions, and ASD/PFO closures
Richard Stack, MD
Founded the Duke University Interventional Cardiology program, which along with being one of the first in the US, has grown to be the one of the largest and best-known programs in the world

Invented or co-invented over 50 major medical products sold worldwide and holder of more than 200 patents

Founded Synecor after two decades of collaboration with leading cardiologists, clinician-inventors, and scientists from across the nation and as an outgrowth of close working relationships among corporate leaders in the medical device industry, and experts at Duke University 
Image of the Structural Heart Imaging Center logo
State-of-the-art, specialized imaging capabilities that mimics the actual clinical setting for complex cardiovascular and structural heart studies.

Publications

Initial in-human experience with the conveyor cardiovascular system for the delivery of large profile transcatheter valve devices
Brian P O'Neill, Dee Dee Wang, Thomas G Caranasos, W Randolph Chitwood Jr, William W O'Neill, Richard Stack
Three patients underwent transcatheter mitral valve replacement with a SAPIEN-3 valve. One patient each underwent transcatheter aortic valve (TAVR) implantation with a SAPIEN 3 and 1 patient underwent TAVR implantation with a Lotus valve. All patients underwent successful implantation of the valve and removal of the CCS and valve delivery systems.
View the publication here
Comparison of a new bioprosthetic mitral valve to other commercially available devices under controlled conditions in a porcine model
Dee Dee Wang, MD; Thomas G. Caranasos, MD; Brian P. O'Neill, MD; Richard S. Stack, MD; William W. O'Neill, MD; W. Randolph Chitwood Jr., MD
Rigorous scientific evaluation of surgical mitral bioprostheses is necessary for patient safety. Based on these results, we would advise caution when evaluating manufacturers' advertising. Implications of this study demonstrate a critical need for standardization and scientific evaluation of surgical mitral bioprostheses to ensure optimal outcomes for clinical human implantation.
View the publication here
Initial in-human experience with the conveyor cardiovascular system for the delivery of large profile transcatheter valve devices.
O'Neill BP; Wang DD; Caranasos TG; Chitwood WR Jr.; O'Neill WW; Stack R.
The CCS may facilitate transcatheter valve delivery in patients who were deemed to have challenging structural anatomy. This pilot study demonstrated the feasibility of incorporating this system with multiple different transcatheter valves. Future studies in a broader representation of patients are warranted.
View the publication here

Ready to plan your preclinical study?

CONTACT US